Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.70 |
| ▸ | CA1 | P00915 | 16/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624592 | 0.98 | CA2 (0.68) | CA2CA1MEN1KMT2ANPSR1 | |
| Iodide SCHEMBL28552462 | 0.98 | CA2 (0.68) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL18118194 | 0.94 | CA2 (0.67) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL28345242 | 0.86 | CA2 (0.59) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL3219450 | 0.85 | CA2 (0.54) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL20680957 | 0.84 | KIF11 (0.59) | CA2CA1MEN1KMT2ANPSR1 | |
| Sulfanilamide SCHEMBL27556780 | 0.82 | CA2 (0.61) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL3637984 | 0.82 | CA2 (0.55) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL359066 | 0.82 | KIF11 (0.62) | CA2CA1MEN1KMT2ANPSR1 | |
| SCHEMBL13430564 | 0.82 | CA2 (0.52) | CA2CA1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823052-A | Preparation method of bosentan | 致卓医药科技(北京)有限责任公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-114614058-B | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-114605337-B | Preparation method of high-purity bosentan | 重庆医药高等专科学校 | 2024-03-12 | — | — | CN | claimed |
| CN-114907275-A | Preparation method of bosentan | 武汉工程大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114614058-A | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114605337-A | Preparation method of high-purity bosentan | 重庆医药高等专科学校 | 2022-06-10 | — | — | CN | claimed |
| CN-114432903-A | Composite membrane with acid resistance and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-109320441-B | Method for efficiently preparing alkynylamide compound | 江西师范大学 | 2021-01-26 | — | — | CN | claimed |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | PEYMAN ANUSCHIRWAN (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-6313119-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| EP-0841326-B1 | Process for the preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-05-16 | — | — | EP | claimed |
| EP-1049677-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2000-11-08 | — | — | EP | claimed |
| US-6121447-A | STARTING WITH 2-CYANOPYRIMIDINE, WHICH IS PREPARED BY REACTING 2-CHLOROPYRIMIDINE WITH AN ALKALI CYANIDE IN THE PRESENCE OF 1-AZABICYCLO(2,2,2)OCTANE OR 1,4-DIAZABICYCLO(2,2,2)OCTANE | HOFFMANN-LA ROCHE INC. (US) | 2000-09-19 | — | — | US | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| WO-1999037621-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | claimed |
| EP-0841326-A1 | Process for the preparation of pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | SOST, SELPLG, BST2 | CA2 667/4885CA1 957/4885MEN1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.